The FDA granted de novo approval for a neuromodulation device to treat symptoms associated with post-traumatic stress disorder (PTSD). The wearable, non-invasive device -- dubbed Modius Spero -- uses electrical vestibular system stimulation to target specific brain areas. It is prescribed and overseen by a healthcare professional as part of a comprehensive PTSD care plan.
The Department of Veterans Affairs (VA) on Tuesday announced a new clinical trial of methylenedioxymethamphetamine-assisted therapy, more commonly known as MDMA, to evaluate the safety and efficacy when treating current and former military personnel for severe mental health disorders including posttraumatic stress disorder (PTSD) and alcohol use disorder.
The SSP-based model provided rapid access to buprenorphine prescriptions, but precipitated withdrawal was a common complication.
Public sentiment on Regulations.gov supports the United States Drug Enforcement Administration's proposal for cannabis rescheduling, though the majority views the proposed Schedule III classification as inadequate and supports further rescheduling or complete de-scheduling of cannabis.
This study offers novel data on opioid-related medication access for adolescents with illicit fentanyl exposure.
Formalizing FA assessment and diagnosis, and improving reimbursement mechanisms, may reduce potential health inequities between market-driven and publicly funded SUD treatment centers in FA treatment and referral resources.
This study's findings suggest that provision of in-jail MOUD could improve methadone uptake in the community.
Social anxiety and psychiatric concerns are salient barriers to attending a variety of MHG groups and to MHG involvement.
This randomized controlled trial provides the first evidence that a pharmacological intervention, buprenorphine, significantly sustains and enhances the antisuicidal effects of ketamine in MDD.
This review aimed to update current knowledge on causality and risk relationships to inform global and national comparative risk assessments for alcohol.
This article highlights state-level progress toward pharmacist reimbursement since the 2024 manuscript on this topic. A special thanks to the many AAPP members who assisted in the research and authorship of this manuscript which highlights expansion of pharmacist test-and-treat authority, new commercial coverage mandates, explicit Medicaid provider enrollment and reimbursement structures, and broadened scope-of-practice provisions tied to payment.
No summary available
No summary available
This systematic review and meta-analysis indicated a small association between antidepressants and ADHD or ASD.
CMS has formally acknowledged and encouraged the involvement of clinical pharmacists in medication management and deprescribing activities through team-based care models. In newly released billing guidance tied to Deprescribing Services Codes, CMS confirmed that pharmacists can contribute billable time through “incident-to” services provided under physician or non-physician practitioner collaborations.
No summary available
This talk will provide a background on traditional kratom and an overview of the recent proliferation of novel, kratom-derived products. Industry marketing, confused media coverage, and dynamic government policy will be described, as all influence public health responses.
This study provides key insights into the resource/cost requirements for implementing and sustaining each A.S.K.-PrEP strategy.
Police stop-and-search was associated with elevated subsequent overdose risk among PWUD.
In this trial of healthy adults who co-used cannabis and alcohol, cannabis edibles combined with alcohol augmented driving impairment.
This review identified that ketamine treatment was associated with instances of elevated liver enzymes.
These data indicate a need to identify and disseminate successful hospital-based strategies to increase prescribing of MAUD.
This study calculated frequencies and measures of central tendency.
No summary available
No summary available